Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PROCEPT BioRobotics (PRCT) Change in Account Payables (2020 - 2025)

PROCEPT BioRobotics (PRCT) has disclosed Change in Account Payables for 6 consecutive years, with $5.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Account Payables rose 210.3% to $5.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $6.6 million, a 408.92% increase, with the full-year FY2025 number at $6.6 million, up 408.92% from a year prior.
  • Change in Account Payables was $5.9 million for Q4 2025 at PROCEPT BioRobotics, up from -$789000.0 in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $5.9 million in Q4 2025 to a low of -$5.4 million in Q4 2024.
  • A 5-year average of $752800.0 and a median of $396000.0 in 2022 define the central range for Change in Account Payables.
  • Peak YoY movement for Change in Account Payables: plummeted 2819.3% in 2021, then skyrocketed 3722.22% in 2024.
  • PROCEPT BioRobotics' Change in Account Payables stood at -$1.5 million in 2021, then soared by 81.68% to -$284000.0 in 2022, then soared by 2169.01% to $5.9 million in 2023, then plummeted by 191.54% to -$5.4 million in 2024, then skyrocketed by 210.3% to $5.9 million in 2025.
  • Per Business Quant, the three most recent readings for PRCT's Change in Account Payables are $5.9 million (Q4 2025), -$789000.0 (Q3 2025), and -$2.2 million (Q2 2025).